NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal (Committee D) meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 2 December 2020

**Location:** Via Zoom

## Committee members present:

1. Professor Gary McVeigh [Chair] Present for all items
2. Dr Lindsay Smith [Vice Chair] Present for all items
3. Dr Carlo Berti Present for items 3 to 3.5.3
4. Dr Matt Bradley Present for all items
5. Sofia Diaz Present for all items
6. Dr Steve Edwards Present for all items
7. Dr Andrew Hitchings Present for all items
8. Dr Robert Hodgson Present for all items
9. Dr Soo Fon Lim Present for all items
10. Dr Guy Makin Present for all items
11. Professor David Meads Present for all items
12. Giles Monickendam Present for all items
13. Stella O’Brien Present for all items
14. Malcolm Oswald Present for all items
15. Dr John Watkins Present for all items 1 to 2.4.2
16. Tony Wootton Present for all items

## External group representatives present:

Sabine Grimm, Kleijnen Reviews Ltd, Present for items 1 to 2.3

Nigel Armstrong, Kleijnen Reviews Ltd, Present for items 1 to 2.3 & 3 to 3.4.1

Bram Ramaekers, Kleijnen Reviews Ltd, Present for items 3 to 3.4.1

## Professional experts present:

Alisia Bosworth, Patient Expert, nominated by the National Rheumatoid Arthritis Society, Present for items 1 to 2.3

Teresa Shakespeare Smith, Patient Expert, nominated by the National Rheumatoid Arthritis Society, Present for items 1 to 2.3

Professor Maya Buch, Prof of Rheumatology/Director of Experimental Medicine, University of Manchester, Present for items 1 to 2.3

Peter Clark, CDF Clinical Lead, NHS England, Present for items 3 to 3.5.3

Chris Elkington, Patient expert, nominated by Head & Neck Cancer UK, Present for items 3 to 3.4.1

Christopher Curtis, Patient expert, nominated by the Swallows Head & Neck Cancer Charity, Present for items 3 to 3.4.1

Dr Andrew Sykes, Consultant Clinical Oncologist, The Christie Hospital NHS Foundations Trust, Present for items

## Observers present:

Helen Barnett, Senior Editor, NICE Present for items 3 to 3.5.3

## Introduction to the meeting

The chair welcomed members of the committee and other attendees present to the meeting.

## Appraisal of Filgotinib for treating moderate to severe rheumatoid arthritis [ID1632]

### Part 1 – Open session

The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Gilead Sciences.

The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Professor David Meads declared a non-financial professional and personal interest as the university of Leeds has received funding from Sanofi and AbbVie for research in an unrelated area.
* It was agreed that David’s declaration would not prevent him from participating in this section of the meeting.
* Dr Matt Bradley declared a non-financial and personal interest as his company is developing a medicine for rheumatoid arthritis. Due to the timings of the work and the timelines for the related NICE appraisals he feels it is unlikely that he or the company can benefit from any knowledge gained from this appraisal.
* It was agreed that Matt’s declaration would not prevent him from participating in this section of the meeting.
* Professor Maya Buch declared direct financial and indirect non-financial interests as research grants have been paid to her employer [University of Leeds] from Pfizer, Roche and UCB, she has provided expert advice at advisory boards and received consultation fees from AbbVie, EMD Serono and Sanofi and received sponsorship to attend meetings [including future meetings] at Boehringer Ingelheim [2019] Abbvie and Gilead [2020].
* It was agreed that Maya’s declarations would not prevent her from participating in this section of the meeting.
* No further conflicts of interest were declared for this appraisal.

The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.

The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2 – Closed session [company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting]

The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached by consensus.

The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy - CDF Review of TA490 [ID1585]

### Part 1 – Open session

The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Bristol-Myers Squibb.

The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Professor David Meads declared a non-financial professional and personal interest as the University of Leeds has received funding from Sanofi and AbbVie for research in an unrelated area.
* It was agreed that David’s declaration would not prevent him from participating in this section of the meeting.
* No further conflicts of interest were declared for this appraisal.

The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.

The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2a – Closed session [members of the public were asked to leave the meeting]

The committee discussed confidential information submitted as part of this appraisal

Part 2b – Closed session [ERG, Clinical & Patient experts and the Company were asked to leave the meeting]

Agreement on the content of the Final Appraisal Determination [FAD] was discussed by the committee.

The committee decision was based on consensus.

The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## Date of the next meeting

The next meeting of the Technology Appraisal (Committee C) will be held on Tuesday 12 January 2021.